The current first-line regimen for treating tuberculosis (TB) recommended by WHO showed poor treatment outcome in patients with isoniazid-resistant TB. A recent study revealed that treatment of isoniazid-resistant tuberculosis with the recommended regimens of first-line drugs might be suboptimal and its high time to find out some new regimen for treating these patients. A recent study has updated a previous systematic review of treatment outcomes associated with the use of first-line drugs in a patient with tuberculosis that is resistant to isoniazid.
They performed cohort studies containing results of standardized treatment of a patient with confirmed isoniazid resistant tuberculosis (but not multidrug-resistant tuberculosis—i.e. not resistant to rifampicin) and the treatment failure and relapse of disease were confirmed. The drug-sensitive tuberculosis patients were also included in…
